Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous DC Vaccination for Chronic HCV
NCT03119025Phase 2Completed
- Sponsor
- Russian Academy of Sciences
- Start
- May 2015
- Primary completion
- Feb 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cells pulsed with hepatitis c virus core and nonstructural protein 3 antigens in hepatitis C (HCV), sponsored by Russian Academy of Sciences. Primary endpoint: Number of Participants With Severe Adverse Reactions and/or With Abnormal Clinical Laboratory Values That Are Related to Treatment at 13 months. Started May 2015; status: completed.
02
Drugs
autologous dendritic cells pulsed with hepatitis c virus core and nonstructural protein 3 antigens
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03119025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119025.